The Tapering Dose of Luspatercept in Patients With Lower-risk Myelodysplastic Syndromes
Condition: Lower Risk MDS Per IPSS-R Intervention: Drug: Luspatercept Sponsors: Institute of Hematology & Blood Diseases Hospital; Beijing Health Alliance Charitable Foundation Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials